IRS Grants for Qualifying Therapeutic Discovery Projects


The IRS’ Section 48D for Qualifying Therapeutic Discovery Projects provides for grants to deserving organizations in their work in various fields of research and development. Two of such organizations that have received grants of late are Peregrine Pharmaceuticals Inc. and CombiMatrix Corporation.

Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing frst-in-class monoclonal antibodies for the treatment of cancer and viral infections. They received a grant amounting to $977,917 for their work in various projects that include research and treatment of patients with second-line non-small cell lung cancer, patients with front-line nonsmall cell lung cancer and patients co-infected with hepatitis C virus (HCV)/HIV under their Bavituximab project and the Cotara(R) project for the treatment of patients with glioblastoma multiforme (GBM). Nearly all of the grant will be disbursed immediately to Peregrine.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Darrin Mish, Tampa Tax Attorney, The Law Offices of Darrin Mish, P.A. | Attorney Advertising

Written by:


The Law Offices of Darrin Mish, P.A. on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.